7 news items
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REPL
23 May 24
-) and GM-CSF to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
REPL
16 May 24
response rate (ORR) of 34.8% (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses).RP1 monotherapy was well
Replimune Group Presented The Interim Results From The ARTACUS Clinical Trial Of RP1 Monotherapy In Solid Organ And Hematopoietic Cell Transplant Recipients With Skin Cancers At AACR 2024
REPL
8 Apr 24
In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate (ORR) of 34.8 percent (8 of 23
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
REPL
7 Apr 24
of Cancer (SITC). In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate (ORR) of 34.8
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REPL
4 Apr 24
death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity
4xu8jqkofau71lm4qfjxp0j2yxp9hu0ml0atkqx6jn
REPL
26 Mar 24
launches in various roles of increasing responsibility across marketing, sales, and franchise management. Prior to joining Replimune, Dr. Patel
ax5zwhg2ex31
REPL
6 Mar 24
immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic
- Prev
- 1
- Next